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The ubiquitin-editing enzyme A20 controls NK cell
homeostasis through regulation of mTOR activity
and TNF
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Manon Vanheerswynghels1,4, Kim Deswarte1,4, Justine Van Moorleghem1,4, Sofie De Prijck1,4, Nozomi Takahashi6,7, Peter Vandenabeele6,7,
Louis Boon8, Geert van Loo6,9, Eric Vivier10,11, Bart N. Lambrecht1,3,4,12**, and Sophie Janssens2,3,4**
The ubiquitin-editing enzyme A20 is a well-known regulator of immune cell function and homeostasis. In addition, A20
protects cells from death in an ill-defined manner. While most studies focus on its role in the TNF-receptor complex, we here
identify a novel component in the A20-mediated decision between life and death. Loss of A20 in NK cells led to spontaneous
NK cell death and severe NK cell lymphopenia. The few remaining NK cells showed an immature, hyperactivated phenotype,
hallmarked by the basal release of cytokines and cytotoxic molecules. NK-A20−/− cells were hypersensitive to TNF-induced cell
death and could be rescued, at least partially, by a combined deficiency with TNF. Unexpectedly, rapamycin, a well-
established inhibitor of mTOR, also strongly protected NK-A20−/− cells from death, and further studies revealed that A20
restricts mTOR activation in NK cells. This study therefore maps A20 as a crucial regulator of mTOR signaling and underscores
the need for a tightly balanced mTOR pathway in NK cell homeostasis.
Introduction
Natural killer (NK) cells are the cytotoxic members of the het-
erogeneous population of innate lymphoid cells (ILCs; Vivier
et al., 2018). NK cells kill target cells via the binding of death
receptors or by the release of lytic granules that contain gran-
zymes and perforin. They also regulate the function of other
immune cells by producing chemokines and cytokines such as
TNF and IFNγ (Vivier et al., 2008). Under normal conditions,
their activation is inhibited by ligands expressed on healthy cells
that engage germline-encoded inhibitory receptors on the NK
cells. Viral infection (Waggoner et al., 2016), malignant trans-
formation (Vivier et al., 2012), or cellular stress (Raulet and
Guerra, 2009) can lead to up-regulation of ligands that are
recognized by a vast array of activating receptors. The relative
balance of inhibitory and activating signals eventually de-
termines the activity of the NK cell. Several signaling pathways
have been identified to play a crucial role in NK cell functioning.
Recently, the mechanistic target of rapamycin (mTOR) pathway
was shown to be a hallmark of NK activity (Marçais et al., 2014,
2017). Although NK cell activation has been studied thoroughly,
relatively little is known about how activated NK cells are
switched off after termination of an inflammatory response.
The NF-κB family of transcription factors plays a key role
in inflammatory responses triggered by a plethora of signaling
receptors. NF-κB dimers induce expression not only of a large
proinflammatory gene program, but also of their own nega-
tive regulators, such as inhibitor of κB (IκB) or A20 (encoded
by the gene TNFα induced protein 3 (Tnfaip3; Renner and
Schmitz, 2009). Absence of A20 leads to prolonged NF-κB
activation and elevated production of inflammatory cytokines
(Catrysse et al., 2014). A20-deficient mice show widespread
tissue inflammation and perinatal death (Lee et al., 2000).
Also in humans, polymorphisms in the Tnfaip3 gene are
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associated with a number of inflammatory and autoimmune
conditions (Catrysse et al., 2014). Conditional deletion of A20
in a vast array of cell types revealed that loss of A20 is asso-
ciated with exacerbated inflammatory responses and, de-
pending on the cell type, autoimmunity (for references, see
Catrysse et al., 2014). In addition, A20 plays a critical role in
the development and differentiation of lymphocytes (Chu
et al., 2011; Onizawa et al., 2015; Drennan et al., 2016). Be-
sides its role in regulating inflammation, A20 protects cells
from necroptosis and TNF-induced apoptosis, in an as yet ill-
defined manner (Opipari et al., 1992; Lee et al., 2000;
Vereecke et al., 2010; Onizawa et al., 2015; Catrysse et al.,
2016).
Being guarded by a delicate balance between inhibitory and
activating signals, NK cells might be particularly sensitive to a
regulator such as A20, and we here set out to determine A20’s
role in NK cells by specific ablation using Cre-lox technology.
Unexpectedly, Ncr1 (NKp46)-mediated deletion of A20 led to
severe NK cell lymphopenia. The few A20-deficient remaining
NK cells were hyperactive and more sensitive to TNF-induced
cell death. Furthermore, A20-deficient NK cells showed high
baseline activation of the mTOR signaling pathway, and treat-
ment with rapamycin in vivo rescued A20-deficient cells from
death. Our data therefore classify A20 as a bona fide regulator of
mTOR signaling and show that a tight regulation of mTOR sig-
naling is crucial for proper NK cell homeostasis.
Results and discussion
Absence of A20 leads to severe NK cell lymphopenia
NK-A20−/− mice were generated by crossing Ncr1iCre/+ mice
(Narni-Mancinelli et al., 2011) to mice bearing loxP-flanked
exons IV and V of the A20 gene (Vereecke et al., 2010), leading
to loss of A20 in all NKp46+ cells (Fig. 1 A). NK-A20−/−mice were
born at normal Mendelian inheritance and developed to adult-
hood normally. Gene expression analysis confirmed specific loss
of A20 in NK cells only (Fig. 1 A). Immunophenotyping of the
NK-A20−/−mice revealed an almost complete absence of NK cells
in all organs examined (Fig. 1 B). The A20-mediated effect was
not dose dependent, as intermediate levels of A20 in the NK-
A20+/− mice (Fig. 1 A) were sufficient for proper NK cell ho-
meostasis (Fig. 1, B and C). Neither T or B cells, nor any other
immune cell population, were affected in NK-A20−/− mice (Figs.
1 A and S1 B). A few other NKp46+ ILC subsets, ILC1s and ILC3s,
also become targeted by the Ncr1-promotor driven Cre expres-
sion (Narni-Mancinelli et al., 2011). ILC1s, a relatively abundant
population of ILCs in the liver, were also drastically affected by
the loss of A20, while proportions of ILC3s in the lamina propria
of the small intestine (LP-SI) remained unaltered (Fig. S1, C–F).
In both liver and LP-SI, conventional NK cells (cNKs) were af-
fected, confirming widespread NK cell lymphopenia.
The generation of bone marrow (BM) chimeras (Fig. 1 D)
confirmed that the observed defect in NK cell survival was cell
intrinsic and that, again, no effect could be observed in NK-
A20+/− cells (Fig. 1, E–G). In conclusion, these data show that
complete absence of A20 in NK cells results in severe NK lym-
phopenia, in a cell-intrinsic manner.
A20-deficient NK cells are hyperactive
NK cells differentiate through a series of maturation stages,
which can be traced in vivo by the sequential acquisition and
loss of specific cell surface receptors. Immature NK cells are
defined by the presence of CD27 and absence of CD11b (CD11blo),
while fully mature NK cells gain CD11b and lose CD27 expression
(CD27lo; Kim et al., 2002; Hayakawa and Smyth, 2006;
Chiossone et al., 2009; Fig. 2 A). Although NK cell numbers were
severely decreased in each maturation stage (Fig. 2 A, lower
panel), the relative proportions of the different substages
changed dramatically, and residual NK cells in the spleen of NK-
A20−/− mice displayed a marked shift toward the immature
phenotype (Fig. 2 A, contour plot and middle panel). Further-
more, A20-deficient NK cells showed a highly proliferative
phenotype as assessed by Ki-67 expression (Fig. 2 B, upper
panel). This enhanced proliferation was not a direct conse-
quence of having lower numbers of NK cells in an attempt to fill
up the empty niche, as A20-deficient NK cells in mixed BM
chimeric mice reconstituted with WT and NK-A20−/− BM also
showed increased Ki-67 expression (Fig. 2 B, lower panel).
We then performed functional studies and tested intracellular
IFNγ production and degranulation, as measured by cell-surface
CD107a expression, a lysosomal marker that translocates to the
cell surface upon degranulation (Alter et al., 2004). Evenwithout
prior stimulation, NK-A20−/− mice displayed a hyperactive
phenotype as revealed by the enhanced proportion of CD107a+
and IFNγ+ NK-A20−/− cells in steady state (Fig. 2 C). Ex vivo
restimulation with plate-bound antibodies against NK1.1 or with
the cytokines IL-12/IL-18 or IL-12/IL-2 triggered a higher degree
of degranulation in the absence of A20. The proportion of IFNγ+
cells was not altered, but we noticed that IFNγ expression levels
on a per-cell basis were strongly elevated in NK-A20−/− cells
(Fig. 2 C). Finally, we also assessed NF-κB activation, using
phosphorylation of Ser536 on p65 (P-p65) as readout. Both in
steady state and upon TNF activation, levels of P-p65 were
markedly increased in the absence of A20 (Fig. 2 D), as expected
from A20’s known NF-κB inhibitory function.
In summary, these data show that the few remaining NK cells
in the NK-A20−/− mice showed a relatively immature phenotype
but were hyperactive, as revealed by increased proliferation,
increased cytokine production, increased degranulation, and
increased signs of NF-κB activation, both in steady state and
upon ex vivo restimulation.
A20 is indispensable for NK cell survival
Our results thus far showed that NK-A20−/− mice have severe
NK cell lymphopenia. To assess whether A20 might affect NK
cell survival, we first examined the viability of freshly isolated
splenocytes by staining with annexin V and a viability marker.
We consistently measured decreased viability of A20-deficient
NK cells, accompanied by slightly activated caspase 3 levels (Fig.
S2, A and B). To follow the fate of NK-A20−/− cells over time, we
generated a tamoxifen-inducible A20 knockout mouse by
crossing LoxP-flanked A20 mice to the ERT2-Cretg/+ mouse line.
As full A20 deletion is lethal (Lee et al., 2000), we enriched NK
cells from the spleens of these mice (CD45.2 A20fl/fl × ERT2-Cre+
or ERT2-Cre−) and mixed them with enriched NK cells from
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Figure 1. Genetic ablation of A20 in NKp46+ cells leads to severe NK cell lymphopenia. (A) Graphical representation and validation by RT-qPCR of the NK-
A20 mouse model. Bar graphs represent A20 RNA expression as measured in sorted splenic lymphocyte populations. Expression was normalized to the in-
dicated housekeeping genes. (B and C) Flow cytometry analysis to assess NK cell percentages in the indicated organs and absolute numbers of splenic
lymphocyte populations in NK-A20 mice. (D) Graphical representation of NK-A20 mixed BM chimeric setup. (E–G) FACS plots and bar graphs represent
percentages or ratios of CD45.1.2+ and CD45.2+ B cells or NK cells as retrieved from the spleens or indicated organs of mixed BM chimeras. For all figures, bar
graphs represent mean ± SD, and dots represent individual mice. Data are representative of at least two independent experiments, with the exception of A,
middle panel. Unpaired Student’s t tests: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 2. Loss of A20 renders NK cells relatively immature and highly hyperactive. (A–D) Flow cytometry analysis of splenic NK cells isolated from NK-
A20 mice. (A) FACS plots and bar graphs represent percentages and absolute numbers of NK cell subsets, determined by CD11b/CD27 expression. CD11blo,
CD11bloCD27hi, immature; DP, CD11bhiCD27hi, double positive (DP) or intermediate; CD27lo, CD11bloCD27hi, mature. (B) Ki-67 expression as measured in splenic
NK cells from NK-A20 mice (top) or mixed BM chimeric mice (bottom). (C) Bar graphs depict percentages of CD107a+ or IFNγ+ NK cells and IFNγ geometrical
mean fluorescence intensity (MFI) within IFNγ+ NK cell population. (D) P-p65 MFI on gated splenic NK cells as measured by phosphoflow immediately after
isolation or upon TNF stimulation. For all figures, bar graphs represent mean ± SD, and dots represent individual mice. Data are representative of at least two
independent experiments. Unpaired Student’s t test: **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Vetters et al. Journal of Experimental Medicine 2013
A20 controls NK homeostasis through mTOR and TNF https://doi.org/10.1084/jem.20182164
CD45.1 congenic control mice (Fig. 3 A). This mix was adoptively
transferred to CD45.1.2 congenic acceptor mice that were sub-
sequently injected i.p. with tamoxifen for 5 d consecutively.
Acceptor mice were bled on days 1, 4, 7, and 10 to determine the
ratio of CD45.2 to CD45.1 donor NK cells, which was compared to
the ratio before injection (Fig. 3 A, flow panels and survival
curve). This analysis showed that upon tamoxifen injection,
ERT2-Cre+ NK cells lost A20 expression from day 2 onwards
(Fig. 3 A, bar graph) and were rapidly depleted, unequivocally
demonstrating the essential role for A20 in NK cell survival
(Fig. 3 A).
NK cell homeostasis depends on IL-15 signaling, which drives
expression of the antiapoptotic protein Mcl-1 and inhibits ex-
pression of proapoptotic Bim (Huntington et al., 2007; Sathe
et al., 2014). Under IL-15–depriving conditions, this delicate
balance of pro- and antiapoptotic Bcl-2 family members is dis-
turbed: Bim and Noxa levels rise, while Mcl-1 levels go down.
Ectopic Bcl-2 expression restores this balance and can inhibit NK
cell apoptosis (Cooper et al., 2002; Minagawa et al., 2002). To
determine potential changes in expression of Bcl-2 family
members in the absence of A20, we analyzed their expression
specifically in the CD11blo subset, to avoid any potential bias
due to the skewed maturation of A20−/− NK cells. While levels of
Bcl-2, Bcl-xL, Mcl-1, XIAP, cIAP1, and Bim appeared largely
unaffected, we found a marked increase in the levels of the
proapoptotic molecule Noxa in A20−/− NK cells (Fig. S2 C). To
determine if Bcl-2 can restore NK cell survival in the absence of
A20, NK-A20−/− mice were crossed with H2K-bcl-2 transgenic
mice expressing human Bcl-2 in all hematopoietic cells including
NK cells (Domen et al., 1998). Bcl-2Tg/+ mice displayed spleno-
megaly, and numbers of splenic NK cells were elevated com-
pared with littermate control mice, as described for other
hematopoietic cells (Domen et al., 2000). Notably, the NK cell
fold expansion induced by ectopic Bcl-2 expression was signif-
icantly higher in A20−/− compared with A20+/+ NK cells (7.6- vs.
1.5-fold; Fig. 3 B, lower panel), suggesting that A20-deficient NK
cells die, at least partially, through an apoptotic pathway de-
pendent on proapoptotic BH3-only proteins. NK cell numbers
were never completely rescued by overexpression of Bcl-2,
suggesting that other Bcl-2 family members such as Mcl-1 might
play a nonredundant role or that other pathways independent of
the intrinsic apoptotic pathway are relevant as well for cell death
induced by loss of A20.
Recently, it was shown that in activated T lymphocytes, A20
ubiquitinates receptor-interacting serine/threonine protein ki-
nase 3 (RIPK3) and, as such, protects T cells from dying by
necroptosis (Onizawa et al., 2015). To assess whether A20-
deficient NK cells also die by necroptosis, we first used a
chemical approach relying on the use of the RIPK1 inhibitor
necrostatin, a well-established inhibitor of necroptosis
(Degterev et al., 2008). As can be seen in Fig. S2 D, treatment of
adoptively transferred ERT2-Cre+ NK cells with necrostatin for
6 d consecutively during tamoxifen-induced A20 deletion did
not rescue NK cell death. To definitely exclude a potential role
for RIPK3, we employed a complementary genetic approach and
generated NK-A20−/− × RIPK3−/− mice. The loss of RIPK3 on top
of A20 did not restore NK cell numbers, showing that A20-
deficient NK cells do not die in a RIPK3-dependent manner
(Fig. 3 C). Overall, these data reveal that A20-deficient NK cells
die through apoptosis in a RIPK3- and RIPK1-independent
manner.
A20-deficient NK cells are more sensitive to TNF
A20 deficiency has been shown before to sensitize hepatocytes
and enterocytes to TNF-induced cell death (Vereecke et al., 2010;
Catrysse et al., 2016). Although these cell types do not die
spontaneously upon loss of A20, widespread apoptosis can be
observed upon injection of sublethal doses of TNF or in combi-
nation with myeloid-specific loss of A20, which leads to in-
creased serum levels of TNF (Vereecke et al., 2014). Importantly,
NK cells express the p55 TNFRI on their cell surface (Fig. S3 A),
and a TNF dose titration experiment on ex vivo–cultured sple-
nocytes showed that A20−/− NK cells are also hypersensitive to
TNF-induced cytotoxicity (Fig. 3 D). What is the source of TNF?
Similar to what we found for IFNγ, NK-A20−/− cells displayed
enhanced levels of intracellular TNF at baseline (Fig. S3 B);
however, this was not reflected by increased serum TNF levels
or enhanced TNF secretion in ex vivo cultures (Fig. S3, C and D).
As a positive control, we used serum from A20mZnF7 mice
(mouse line described in Fig. 5). Still, this did not exclude the
possibility that NK cells would be sensitized to TNF secreted by
other cell types. To assess the role of TNF in NK cell death, we
injected CD45.1 acceptor mice for 6 d consecutively with a TNFα
antibody during the treatment with tamoxifen to delete A20 in
adoptively transferred ERT2-Cre+ NK cells. As can be seen in
Fig. 3 E, concomitant blocking of TNF-mediated signaling
pathways partially rescued NK cell death induced by loss of A20.
In a complementary genetic approach, we generated compound-
deficient NK-A20−/− × TNF−/−mice. Similar to what we found for
the Bcl2Tg/+ mice, loss of TNF by itself is sufficient to increase
NK cell numbers in the spleen already at baseline (Fig. 3 F).
Notably, the rescue of A20-deficient NK cells by compound
deficiency of TNF is considerably higher, implementing a TNF-
dependent apoptotic pathway in the cell death induced by loss of
A20. Still, additional loss of TNF did not restore A20−/− NK cell
numbers back to WT NK cell numbers in the spleen, suggesting
that A20 acts at multiple levels in the protection against
cell death.
A20-deficient NK cells display elevated mTOR activation
As NK cell homeostasis is intricately associated with IL-15 and
STAT5 signaling (Cooper et al., 2002; Vosshenrich et al., 2005;
Eckelhart et al., 2011), we assessed whether A20 might modulate
this pathway. The phosphorylation status of STAT5 was not
different between NK-A20−/− and littermate NK cells either in
basal conditions or upon stimulation with IL-15, indicating that
signaling immediately downstream of the IL-15 receptor was not
affected by loss of A20 (Fig. 4 A). Along these lines, the levels of
CD122 (IL-2/IL-15 receptor β chain) were unaltered in NK-
A20−/− cells (data not shown). Recent data implemented a role
for the metabolic checkpoint kinase mTOR in IL-15–dependent
signaling (Marçais et al., 2014). Notably, in T cells, mTOR ac-
tivity was enhanced upon loss of A20 (Matsuzawa et al., 2015).
Also, NK-A20−/− cells showed strongly enhanced mTORC1
Vetters et al. Journal of Experimental Medicine 2014
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activity as evidenced by increased phosphorylation of down-
stream mTOR substrates 4EBP1 and S6, which was particularly
prominent in steady state (Fig. 4 A). Also, other targets of mTOR
signaling, such as cell surface expression of the transferrin re-
ceptor CD71 or the amino acid transporter CD98, were markedly
elevated, while ex vivo incubation of splenocytes with the
fluorescent glucose analogue 2-NBDG revealed that NK-A20−/−
cells displayed increased glucose uptake (Fig. 4 B). In line with
these data, NK-A20−/− cells showed increased in vivo protein
synthesis, as revealed by O-propargyl puromycin (OP-Puro)
incorporation in mixed BM chimeric mice (Fig. 4 C; Signer et al.,
2014; Tavernier et al., 2017). Overall, these data indicate that A20
acts as a metabolic checkpoint inhibitor in NK cells.
To assess whether this enhanced mTOR activity was con-
tributing to the observed NK-A20−/− cell death, we injected
CD45.1 acceptor mice for 6 d consecutively with rapamycin, an
established inhibitor of mTORC1, to see if we could restore
tamoxifen-induced cell death of ERT2-Cre+ A20-deficient NK
cells. As can be seen in Fig. 4 D (middle panel), we obtained a
clear rescue of A20−/− NK cells by damping the exacerbated
mTOR signaling by rapamycin, classifying mTOR as a bona fide
target in the A20-mediated decision between life and death.
To test whether the TNF and mTOR pathways act indepen-
dently or belong to one and the same pathway, we concomitantly
blocked both TNF and mTOR during the tamoxifen-induced
deletion process of A20 and assessed whether the two in-
hibitors worked synergistically. As can be noted from Fig. 4 D
(lower panel), each inhibitor individually rescued part of the NK
cells, but together they led to a complete restoration of NK cell
death induced by loss of A20. This suggests that both TNF hy-
persensitivity and exacerbated mTOR signaling contribute sep-
arately to NK cell death in conditions of A20 deficiency.
A20 comprises a deubiquitinase domain as well as ubiquitin-
binding domains. Our department recently generated a ubiqui-
tous zinc finger 7 (ZnF7) knock-in mouse model for A20, in
which cysteine residues 764 and 767 in ZnF7 domain were mu-
tated (referred to as A20mZnF7) to abrogate binding of A20 to
linear ubiquitin chains in all cells (Polykratis et al., 2019).
A20mZnF7/mZnF7 mice suffer from massive hyperinflammation
and develop arthritis, similar to mice deficient for A20 in my-
eloid cells (Polykratis et al., 2019). To elucidate how A20 medi-
ates its homeostatic role in NK cells, we immunophenotyped the
splenic NK cell compartment in the A20mZnF7/mZnF7 mice and
found that impairment of A20 linear ubiquitin binding causes
massive cell death in NK cells (Fig. 5 A). Similar to what was
shown in NK-A20−/−mice, mTOR activity was highly elevated in
A20mZnF7/mZnF7 cells (Fig. 5 B), while intracellular TNF levels in
A20mZnF7/mZnF7 cells did not differ (Fig. 5 C). However, at the
serum level, we found a massive increase in TNF in the
A20mZnF7/mZnF7 mice (Fig. S3 C).
In summary, we unraveled a cell-intrinsic role for A20 in
controlling NK cell survival by acting on the TNFRI and mTOR
complexes. Constitutive loss of A20 in NK cells led to severe and
widespread NK cell lymphopenia due to NK cell death. Re-
maining NK cells were hyperactive and hyperproliferative,
produced more proinflammatory cytokines, and had increased
cytotoxic properties. Despite the well-established anti-apoptotic
role of A20 (Lee et al., 2000), NK cells are, to our knowledge, the
first cell type that die in a spontaneousmanner upon loss of A20.
B cells and dendritic cells show strongly enhanced survival, due
to the up-regulation of Bcl-2 and Bcl-xL, and are even more
resistant to Fas-induced cell death (Tavares et al., 2010; Kool
et al., 2011). Strikingly, despite strongly enhanced activation of
the NF-κB pathway in NK-A20−/− cells (as monitored by P-p65
levels), antiapoptotic NF-κB–dependent genes were not induced,
showing complex regulation of NF-κB transcriptional activity in
NK cells. In T cell–specific conditional A20−/− mice, frequency
and numbers of CD4+CD8+ double-positive thymocytes, CD8+ or
CD4+ single-positive thymocytes, and peripheral T cells were
normal (Onizawa et al., 2015). Only upon TCR triggering could
marked reductions in T cell numbers be observed, suggesting
that A20 was needed to protect activated T cells from dying
(Onizawa et al., 2015). Similarly, in hepatocytes and enterocytes,
loss of A20 did not lead to spontaneous cell death, but rather
caused hypersensitivity to sublethal doses of TNF (Vereecke
et al., 2010; Catrysse et al., 2016). In NKT cells, A20 controlled
survival of NKT1 and NKT2 to some extent, and not NKT17
subsets, but never led to the dramatic cell loss observed for NK-
A20−/− cells (Drennan et al., 2016). Loss of A20-deficient
NKT cells could be prevented by compound deficiency with
MALT1, a proteolytic enzyme in the Carma-Bcl10-Malt1 complex
downstream of the TCR and a well-established target of A20.
However, this pathway appeared not to be involved in A20-
mediated cell death of NK cells (data not shown). Part of the
mechanism leading to spontaneous loss of NK cells in the ab-
sence of A20 was explained by the hyperactivated state of
A20−/− NK cells, which led to increased proinflammatory TNF
production, either direct or indirect. Due to the loss of A20 and
Figure 3. A20 is indispensable for NK cell survival. (A) Graphical representation of adoptive cell transfer setup. FACS plots show the frequency of CD45.1
and CD45.2 donor NK cells, and survival graph shows CD45.2/CD45.1 donor NK cell ratios compared with day 0 as measured over time in the blood. Bar graph
depicts normalized A20 RNA expression as determined by RT-qPCR on sorted splenic CD45.1 or CD45.2 donor NK cells upon tamoxifen (tam) or vehicle control
treatment. (B, C, and F) Flow cytometry analysis on splenic NK cells isolated from indicated mouse lines. Bar graphs represent NK cell absolute numbers and
the fold expansion, and FACS plots depict the proportion of NK cells per genotype. (D) Freshly isolated NK-A20 splenocytes were subjected to a dose range of
mTNF over time. Survival curves (upper graph) represent NK cell viability as assessed by annexin V and live/dead staining on flow cytometry, and bar graphs
(lower panel) show AUC for indicated mTNF doses per genotype. For readability, significant differences are shown only per genotype but were also evident
between genotypes (****, P < 0.0001 per dose). (E) Graphical representation of adoptive cell transfer setup with indicated treatments. Bar graphs represent
the ratio of donor-derived CD45.2/.1.2 NK cells, relative to the control group, as determined by flow cytometry. All bar graphs represent mean ± SD, and dots
represent individual mice. Data are representative of at least two independent experiments, with exceptions of A (RT-qPCR data) and D, which were performed
only once. Statistics were performed with unpaired Student’s t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. For AUC analyses, see Materials
and methods.
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Figure 4. A20 restricts the metabolic activity of NK cells. (A and B) Flow cytometry analysis of splenic NK cells isolated fromNK-A20 mice. (A) Histograms
show steady state phosphorylation (p-) of indicated proteins in CD11blo NK cells measured by phosphoflow. Bar graphs depict mean fluorescence intensity
(MFI) of phosphorylated proteins in steady state or upon IL-15 stimulation. FMO, fluorescence minus one. (B) Histograms show 2-NBDG uptake and CD71 and
CD98 expression as measured on steady state CD11blo NK cells. Bar graphs depict MFI of the indicated parameters in NK cell subsets. DP, double positive.
(C) Graphical representation of OP-Puro incorporation in NK-A20 BM chimeras. Bar graphs represent OP-Puro fluorescence as measured by flow cytometry in
splenic donor-derived CD45.1.2 (WT) or CD45.2 lymphocyte populations. (D) Graphical representation of adoptive cell transfer setup. Bar graphs depict the
Vetters et al. Journal of Experimental Medicine 2017
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concomitant hypersensitivity to TNF-induced killing, this
caused NK cell death. Still, as was obvious from the compound
deficient NK-A20−/− × TNF−/− mice, NK cell numbers could not
be restored to WT levels, indicating that additional mechanisms
were needed to explain the A20-mediated protection against
cell death.
We turned our attention toward the mTOR signaling cascade,
a pathway that was recently established as a critical regulator of
NK cell homeostasis and considered a hallmark for reactive NK
cells (Marçais et al., 2014, 2017). Loss of A20 dramatically in-
creased mTOR signaling output, as monitored by enhanced
downstream phosphorylation of 4EBP1 and S6, enhanced glucose
uptake, and enhanced translation. This occurred independently
of IL-15 receptor signaling, as both IL-15 receptor levels and
signaling steps immediately downstream of the IL-15 receptor
were unaffected. Rather, we propose that A20 could directly
target either mTOR or any of its regulators in the mTOR sig-
naling complex by ubiquitination, as suggested before for T cells
(Matsuzawa et al., 2015). It has been shown that increased
ubiquitination of mTOR and/or proteins within the mTOR sig-
naling complex are associated with restrained mTOR activity, in
an as yet ill-defined manner (Ivanov and Roy, 2013). Indeed, a
newly generated A20mZnF7 knock-in mouse model confirmed
that ZnF7 is absolutely essential for A20 to restrict mTOR ac-
tivity and preserve NK cell homeostasis, implying a potential
role for A20 in stabilization of M1 ubiquitin chains on mTOR or
associated proteins.
We can only speculate how increased mTOR signaling causes
NK cell death. Activation of mTOR has been associated before
with increased NK cell reactivity, resulting in enhanced calcium
influxes upon triggering of NK activating receptors (Marçais
et al., 2017). Furthermore, increased translation is linked with
increased production of oxygen radicals (Han et al., 2013). While
not formally proven, it is not difficult to conceive that both
calcium overload and ROS production could trigger mitochon-
drial pathways of cell death. Intriguingly, we observed a robust
increase in the expression level of the proapoptotic molecule
Noxa in NK-A20−/− cells and found that the cells could be par-
tially rescued by overexpression of Bcl-2, suggesting at least a
partial contribution of a mitochondrial pathway of death. Fi-
nally, high mTOR activation is also known to interfere with
cytoprotective pathways of autophagy. Preliminary data showed
that deficiency of Atg16L1, a crucial component of autophago-
some formation (Fujita et al., 2008; Adolph et al., 2013), also
causes NK cell loss in a dose-dependent manner (data not
shown). These data confirm that a tight balance of mTOR sig-
naling and autophagy is crucial for proper NK cell homeostasis
(O’Sullivan et al., 2016).
In conclusion, here we established a critical role for A20 in
restricting mTOR activity in NK cells, adding a novel player in
the decision of A20 between life and death.We postulate that NK
cells, being exquisitely sensitive to balances between inhibitory
and activating signals, are particularly vulnerable to any dys-
regulation of these balances and therefore prone to death when a
crucial regulator such as A20 is lost.
Materials and methods
Mice
The Ncr1iCre/+ mouse line was originally described in Narni-
Mancinelli et al. (2011); A20fl/fl mice in Vereecke et al. (2010);
RIPK3−/− in Newton et al. (2004); H2K-bcl-2tg/+ in Domen et al.
(1998); TNF−/− mice in Pasparakis et al. (1996); and A20mZnF7
mice in Polykratis et al. (2019). The ERT2-Cretg/+, CD45.1, and
CD45.1.2 mice are provided by the Jackson Laboratory. The fol-
lowing mouse lines were bred and housed under specific
pathogen–free conditions at the VIB–Ghent University Center
for Inflammation Research: Ncr1+/+ × A20fl/fl, Ncr1iCre/+ × A20+/fl or
A20fl/fl (NK-A20+/+, NK-A20+/−, or NK-A20−/−), NK-A20−/− ×
RIPK3−/−, NK-A20−/− × TNF−/−, A20fl/fl × ERT2-Cretg/+, CD45.1,
CD45.1.2, and A20mZnF7. The NK-A20−/− × H2K-bcl-2tg/+ mouse
line was housed at the Campus Proeftuinstraat Ghent University
site. All transgenic mouse lines have been generated on a C57Bl/6
background (Ncr1iCre/+, A20fl/fl, ERT2-Cretg/+, and A20mZnF7) or
were backcrossed for >10 generations to C57Bl/6 (H2K-bcl-2tg/+,
RIPK3−/−, TNF−/− transgenic mice). All experiments with the NK-
A20 mice were performed with NK-A20+/+ animals as littermate
controls. In the case of adoptive transfers or BM chimeras,
CD45.1/2 congenically marked animals were included as WT
counterparts. All animal experiments were performed in ac-
cordance with institutional guidelines for animal care of the VIB
site Ghent/Ghent University Faculty of Sciences and in accor-
dance with ethical committee EC2014_043. Litters with mice of
both sexes at 6–17 wk of age were used for experiments.
Generation of BM chimeras
CD45.1 recipient mice received two rounds of sublethal irradi-
ation (400 cG) with a time interval of 4 h. At least 4 h after the
second irradiation cycle, recipient mice were injected intrave-
nously with a 50:50 mixture of BM cells (either 2 × 106 or 4 ×
106) derived from CD45.1.2 and NK-A20+/+, NK-A20+/−, or NK-
A20−/− donors. Mice were used for experiments ≥8 wk after
reconstitution.
Preparation of single-cell suspensions
For all figures except Fig. S1, spleens and mediastinal lymph
nodes were smashed over a 70-µM filter, and red blood cells
were removed from the spleen by osmotic lysis. For Fig. S1, an
enzymatic digestion protocol was followed that ensures proper
isolation of the myeloid compartment. Spleens were first
minced, digested for 30 min in RPMI 1640 (Gibco) containing
Liberase TM (0.02 mg/ml; Roche) and DNase I (10 U/ml; Roche)
in a shaking water bath at 37°C, filtered through a 70-µM filter,
and subjected to osmotic lysis. For BM, single-cell suspensions
ratio of donor-derived CD45.2/.1.2 NK cells, relative to the control group, as determined by flow cytometry. For all figures, bar graphs represent mean ± SD, and
dots represent individual mice. Data are representative of at least two independent experiments. Unpaired Student’s t test: *, P < 0.05; **, P < 0.01; ***, P <
0.001; ****, P < 0.0001.
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were obtained by crushing the tibia and femur, followed by lysis
of red blood cells. In the case of lung and liver, organs were
collected from PBS-perfused mice, minced, and digested at 37°C
for 20–45 min in RPMI 1640 (Gibco) containing DNase I (10
U/ml; Roche) and collagenase A (1mg/ml; Sigma-Aldrich). Lungs
required a single GentleMACS dissociation step (after digestion),
while livers were subjected to two rounds of GentleMACS
dissociation (before and after digestion). Red blood cells were
removed by osmotic lysis, and an additional Percoll-gradient
centrifugation step was performed for the liver. To isolate
cells from the lamina propria, the small intestine was dissected,
Peyer’s patches were removed, and the intestine was opened
longitudinally and then minced using scissors. Epithelial cells
were removed by serial washes at 37°C with HBSS without Ca2+
Figure 5. A20 controls NK cell survival and
the mTOR pathway through its ZnF7 domain.
(A–C) Flow cytometry analysis of steady state
splenic NK cells isolated from indicated mouse
lines. (A) Bar graphs depict NK cell absolute
numbers. (B) Histograms and bar graphs depict
MFI of the indicated phosphorylated proteins as
determined by phosphoflow. (C) Bar graphs
show TNF MFI in total NK cells (no prior stimu-
lation). All bar graphs represent mean ± SD, and
dots show individual mice. All data are repre-
sentative of at least two independent experi-
ments, and statistical analysis was performed
with a one-way ANOVA (ad hoc Tukey’s multiple
comparisons test). *, P < 0.05; **, P < 0.01; ***,
P < 0.001; ****, P < 0.0001. (D)Model depicting
the possible role of A20 in NK cells. Upper panel:
Through its Zn fingers, A20 binds and stabilizes
M1-linked ubiquitin chains in the TNF receptor
complex. As such, A20 competes with NF-κB
essential modulator (NEMO) for binding to key
components in the receptor disc and thereby
interferes with NF-κB activation. At the same
time, by stabilizing M1 ubiquitin chains, A20 also
prevents the deubiquitinase cylindromatosis
(CYLD) from degrading linear ubiquitin chains.
This precludes formation of the proapoptotic
complex II. Lower panel: Loss of A20 leads to
strongly enhanced NF-κB activation and release
of cytokines, such as TNF, in either a direct or
indirect manner. Due to the enhanced sensitivity
to TNF-mediated killing in the absence of A20,
NK cells die. Additionally, A20 also restricts
mTOR activity in NK cells, preventing sponta-
neous hyperactivation of this pathway. Loss of
A20 leads to mTOR overactivation and mTOR-
dependent NK cell death, which could be due
to enhanced translation and increased produc-
tion of ROS, to a block in autophagy and/or other
signaling pathways. LUBAC, linear ubiquitination
assembly complex.
Vetters et al. Journal of Experimental Medicine 2019
A20 controls NK homeostasis through mTOR and TNF https://doi.org/10.1084/jem.20182164
andMg2+ (Gibco) containing 10% FCS (Bodinco) and 2 mMEDTA
(Lonza). The lamina propria was subsequently digested at 37°C
for 15–20 min in RPMI 1640 supplemented with 10% FCS, colla-
genase A (0.24 mg/ml; Sigma-Aldrich) and DNase I (50 U/ml;
Roche), followed by Percoll-gradient centrifugation. Tail vein blood
was collected in Microvette 200 K3E tubes (Sarstedt), and red
blood cells were cleared by several rounds of osmotic lysis. Serum
samples were obtained from femoral artery (terminal) bleeding.
Blood was collected in Eppendorf tubes and stored at room tem-
perature for ≥2–3 h. Samples were then centrifuged for 10 min at
5,000 rpm, and supernatant was collected and stored at −20°C.
Flow cytometry and gating strategy
Single-cell suspensions were obtained as described and stained
with monoclonal antibodies labeled with fluorochromes or bio-
tin, recognizing the followingmarkers: activated caspase 3 (C92-
605), CD3 (17A2 or 145-2c11), CD11b (M1/70), CD11c (N418), CD16/
32 (2.4G2), CD19 (1D3), CD27 (LG.7F9 or LG.3A10), CD45 (30-F11),
CD45.1 (A20), CD45.2 (104), CD49a (Ha31/8), CD49b (DX5), CD64
(X54-5/7.1), CD71 (R17217), CD98 (RL388), CD107a (1DB4), CD122
(TM-b1), F4/80 (BM8), IA-IE (M5/114.15.2), IFNγ (XMG1.2), Ki-
67 (B56), NK1.1 (PK136), NKp46 (29A1.4), P-4EBP1 (236B4),
P-AKT (M89-61), PDCA1 (JF05-1C2.4.1), P-p65 (93H1), P-S6K
(D57.2.2E), P-STAT5 (47), Rorγt (AFKJS-9), SiglecF (E50-2440),
TCRβ (H57-597), TCRγδ (eBioGL3), and TNF (MP6-XT22). In-
tracellular stainings for TNF and OP-Puro were performed with
the Foxp3 kit (eBioscience). Lyse/Fix and PermIII buffers (BD)
were used for intracellular stainings of phosphorylated proteins.
Intracellular IFNγ, caspase 3, and Ki-67 stainings were per-
formed with Cytofix/Cytoperm (BD) and Perm/Wash (BD). Cell
viability was measured using annexin V (BD) and/or a fixable
viability dye (eBioscience). Flow cytometry was performed on a
FACS Fortessa 4 or 5 laser (BD Biosciences), and data were an-
alyzed using FlowJo.
The following gating strategy was applied for NK-A20 im-
munophenotyping: B cells (live, CD3−CD19+), T cells (live,
CD19−NK1.1−CD3+), CD4+ T cells (live, CD19−NK1.1−CD3+TCR
γδ−CD4+), CD8+ T cells (live, CD19−NK1.1−CD3+TCRγδ−CD8+),
macrophages (live, CD19−NK1.1−CD3−F4/80+CD64+ auto-
fluorescent), dendritic cells (live, CD19−NK1.1−CD3− [not mac-
rophages] CD11c+MHCII+), NK cells (live, CD19−CD3−NK1.1+),
NK T cells (live, CD19−CD3+NK1.1+), neutrophils (live,
CD19−NK1.1−CD3− [not basophils] CD11b+Ly6G+), eosinophils
(live, CD19−NK1.1−CD3− [not basophils or neutrophils]
CD11c−SiglecF+SSChi), Ly6Chi monocytes (live, CD19−NK1.1−CD3−
[not basophils, neutrophils, or eosinophils] CD11b+Ly6C+), plas-
macytoid dendritic cells (live, CD19−NK1.1−CD3− [not basophils,
neutrophils, eosinophils, or Ly6Chi monocytes] Ly6C+PDCA1+),
and γδ T cells (live, CD19−NK1.1−CD3+TCRγδ+). The following
standard gating strategy was used for NK cells throughout the
article: live, CD19−CD3−NK1.1+CD122+CD49b+. In FACS plots
showing NK cells, numbers depict frequencies of NK cells of total
live cells. Depending on antibody availability, CD122+ was
sometimes replaced by NKp46+, and CD19 was not always added.
For phosphoflow, the following NK cell gating was applied: live,
CD3−NK1.1+NKp46+, or live, CD3−NK1.1+CD49b+. For some
stainings, fluorescence minus one was used as a control.
Cell sorting and gating strategy
Leukocytes were obtained from the spleen as described and,
before sorting, enriched for NK cells with the MagniSort NK cell
enrichment kit (eBioscience) or with an in-house optimized
enrichment procedure using MACS columns (negative selection
with stainings against CD5, CD24, TCRβ, CD19, F4/80, CD3,
Ter119, and Ly6G). For sorting T, B, and NK cells, the obtained
single-cell suspension was divided in two fractions. One fraction
was immediately stained for T and B cells, and the second
fraction was used for NK enrichment before staining. Up to
40,000 cells (T, B, and NK cells) were sorted directly in RLT Plus
Buffer (RNeasy plus micro kit; Qiagen) supplemented with
β-mercaptoethanol (10 µl/ml). Samples were snap frozen and
stored at −80°C until further processing. Cell sorting was per-
formed on a FACS AriaII and III (BD Biosciences). The following
gating strategies were applied: B cells (live, CD19+), T cells (live,
CD19−NK1.1−CD3+), andNK cells (live, CD3−TCRβ−CD19−CD122+NK1.
1+CD49b+, or live, CD3−CD19−TCRβ−NK1.1+NKp46+).
RNA extraction and quantitative RT-PCR (RT-qPCR)
RNA from sorted cells was obtained using the RNEasy Plus
Micro Kit (Qiagen) according to the manufacturer’s instructions.
cDNA was generated with the SensiFAST cDNA Synthesis Kit
(Bioline) or the iScript cDNA synthesis kit (Bio-Rad Laborato-
ries) or amplified with the Ovation PicoSL WTA System V2 kit
(NuGEN) following the manufacturer’s guidelines. Upon am-
plification, pollutants were removed using the MinElute PCR
purification kit (Qiagen) before SybrGreen-based RT-qPCR with
the SensiFast SYBR No-ROX kit (Bioline) on a LightCycler 480
(Roche). The following mouse primers were used: A20, forward
59-AAACCAATGGTGATGGAAACTG-39 and reverse 59-GTTGTC
CCATTCGTCATTCC-39; β-actin, forward 59-GCTTCTAGGCGG
ACTGTTACTGA-39 and reverse 59-GCCATGCCAATGTTGTCT
CTTAT-39; Bcl-2, forward 59-GTACCTGAACCGGCATCTG-39 and
reverse 59-GGGGCCATATAGTTCCACAA-39; Bcl-xL, forward 59-
GACAAGGAGATGCAGGTATTGG-39 and reverse 59-TCCCGT
AGAGATCCACAAAAGT-39; Bim, forward 59-CCCGGAGATACG
GATTGCAC-39 and reverse 59-GCCTCGCGGTAATCATTTGC-39;
cIAP, forward 59-TACGGATGAAGGGTCAGGAGT-39 and reverse
59-GCACCACTGTCTCTGTAGGG-39; GAPDH, forward 59-GCA
TGGCCTTCCGTGTTC-39 and reverse 59-TGTCATCATACTTGG
CAGGTTTCT-39; HPRT, forward 59-TGAAGAGCTACTGTAATG
ATCAGTCAAC-39 and reverse 59-AGCAAGCTTGCAACCTTAACC
A-39; Mcl-1, forward 59-CAAAGATGGCGTAACAAACTGG-39 and
reverse 59-CCGTTTCGTCCTTACAAGAACA-39; Noxa, forward
59-ACTGTGGTTCTGGCGCAGAT-39 and reverse 59-TTGAGCACA
CTCGTCCTTCAA-39; Puma, forward 59-ATGGCGGACGACCTC
AAC-39 and reverse 59-GGAGTCCCATGAAGAGAT-39; and XIAP,
forward 59-GTGGTACCCAGGGTGCAAATA-39 and reverse 59-
TGCTCCCGGATGTTTGGATT-39. mRNA expression levels were
analyzed using qBAse+ software (Biogazelle).
Cell culture and stimulation
For the measurement of IFNγ production and degranulation, 3 ×
106 splenocytes were cultured in RPMI 1640 (Gibco) supple-
mented with 10% FCS (Bodinco) in the presence of GolgiStop
(BD) and anti-CD107a (BD). The cells were cultured in the
Vetters et al. Journal of Experimental Medicine 2020
A20 controls NK homeostasis through mTOR and TNF https://doi.org/10.1084/jem.20182164
presence of cytokines (rmIL-12 at 25 ng/ml [Peprotech], rmIL-18
at 5 ng/ml [Peprotech], and rmIL-2 at 20 ng/ml [Protein Service
Facility, VIB]) or were cultured on antibody-coated plates (anti-
NK1.1 at 10 µg/ml) for 4 h at 37°C. For p-4EBP1 and p-S6 phos-
phoflow, 4 × 106 splenocytes were stimulated for 1 h at 37°C in
the presence or absence of rmIL-15 (100 ng/ml; Peprotech), after
which cell surface stainings were performed as described, fol-
lowed by fixation and intracellular stainings. For steady state
and stimulation-induced P-p65 phosphoflow, 3 × 106 splenocytes
were either stained immediately ex vivo or stimulated for 5 or
15 min at 37°C with 1 or 10 ng/ml mouse TNF (mTNF; Tissue
Culture Core, VIB). Untreated cells were used as controls at these
time points. Culture medium for phosphoflow experiments
consisted of RPMI 1640 supplemented with 10% FCS. For TNF
hypersensitivity, 2 × 106 splenocytes were cultured for 0, 3, 6, 9,
and 12 h at 37°C in tissue culture medium (RPMI 1640, 10% FCS,
Glutamax [Life Technologies], Gentamicin [Gibco], and
β-mercaptoethanol [Tissue Culture Core, VIB]) and supple-
mented with 0, 1, 2.5, or 5 ng/ml mTNF. 9- and 12-h cultures
were supplemented with low-dose rmIL-15 (10 ng/ml; Pepro-
tech). Cell viability was determined by annexin V and live/dead
staining, as described. For glucose uptake, 2 × 106 splenocytes
were incubated for 10 min in RPMI 1640 supplemented with
100 µM of the fluorescent glucose analogue 2-NBDG (Thermo
Fisher Scientific) before staining of cell surface proteins as de-
scribed. For ELISA, 106 splenocytes or enriched splenic NK cells
were cultured for 24 h in tissue culture medium. After 24 h,
supernatant was collected and stored at −20°C.
ELISA
TNF secretion was determined by ELISA (eBioscience) following
the manufacturer’s guidelines. Samples included serum or su-
pernatant from 24-h–cultured enriched NK cells or splenocytes.
See Preparation of single-cell suspensions and Cell culture and
stimulations for further details.
Adoptive cell transfers
NK cells were isolated and enriched from the spleens of CD45.1
(WT) or CD45.1.2 (WT) and A20fl/fl × ERT2-Cre− or Cre+ animals,
and a 1:1 mixture of donor cells (total number of cells: 4–5 × 105)
was given i.v. to congenic recipients. Immediately after cell
transfer, recipient mice were treated with tamoxifen (or corn oil
as control) for 5 d, and in some cases also with indicated
chemical compounds for 6 d consecutively, unless stated oth-
erwise. The ratio of donor NK cells in the blood or spleen of the
recipient animals was determined by flow cytometry. For vali-
dation of the tamoxifen-inducible ablation of A20, donor NK
cells were sorted from the spleens of recipients after 2- or 3-d
tamoxifen treatment, and A20 expression was determined by
RT-qPCR.
Chemical compounds
Tamoxifen (Sigma-Aldrich) was dissolved in corn oil (20mg/ml;
Sigma-Aldrich) and injected i.p. (2 mg/mouse) for 5 d, unless
stated otherwise. Corn oil (Sigma-Aldrich) was used as vehicle
control. Nec1s (100 mM in DMSO; kindly donated by N. Taka-
hashi) was injected i.v. (6.25 mg/kg) after further dilution in
endotoxin-free PBS (Gibco) to reach a final DMSO content of
2.5%. Rapamycin (InvivoGen) was dissolved in DMSO (10 mM),
diluted in endotoxin-free PBS (Gibco), and injected i.p.
(0.6 mg/kg) at a final DMSO content of 1%. TNFα (2.6 mg/ml;
clone XT22; Bioceros) and isotype control (rat IgG1; clone GL113;
1.9 mg/ml; Bioceros) were diluted in endotoxin-free PBS (Gibco)
and injected i.p. (10 mg/kg). Treatment with one of the above
compounds started 1 d after the start of the tamoxifen treatment
and lasted 6 d.
Measurement of protein synthesis
OP-Puro (Jena Bioscience) was dissolved in DMSO, further di-
luted in endotoxin-free PBS (50 mg/ml; Gibco), and injected i.p.
(50 mg/kg). 1 h after injection, mice were euthanized, and
lymphocytes were obtained from the spleens as described above.
5 × 106 cells were stained for surface markers and subsequently
fixed and permeabilized using the Foxp3 kit (eBioscience). For
OP-Puro labeling, Alexa Fluor 647 picolyl azide (AF647 PCA;
Thermo Fisher Scientific) was chemically linked to OP-Puro
through a copper-catalyzed azide-alkyne cycloaddition. In
short, 0.5 µM AF647 PCA was dissolved in the Click-iT Cell
Reaction Buffer (Thermo Fisher Scientific) containing 200 µM
CuSO4. Immediately after preparation, cells were incubatedwith
this mixture at room temperature. After 10-min incubation, the
reaction was quenched by addition of PBS supplemented with
5% FCS (Bodinco) and 5 mM EDTA (Lonza). Cells were washed
twice to remove unbound AF647 PCA.
Statistical analyses
Datasets were analyzed with two-tailed unpaired Student’s
t test, Mann–Whitney U test (i.e., nonparametric analogue of
Student’s t test), or one-way ANOVA combined with Tukey’s
multiple comparisons test. For TNF hypersensitivity, we per-
formed area under the curve (AUC) analysis on normalized data,
determined by the ratio of live cells at a given time point (3, 6, 9,
or 12 h) to live cells at the start of the experiment (0 h). Ratios
were determined per biological replicate per dose. Ad hoc un-
paired Student’s t tests were performed on average normalized
AUC data per dose per genotype. All statistical tests were per-
formed with Prism (GraphPad Software), and P values express
the levels of significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001;
****, P < 0,0001). Error bars represent the SD.
Online supplemental material
Fig. S1 shows the immunophenotyping of different immune cell
populations in spleen, liver, and LP-SI of NK-A20 mice. Fig. S2
shows an overview of apoptotic markers in A20-deficient NK
cells and the effect of necroptosis inhibition in an adoptive
transfer setting. Fig. S3 describes TNF levels in A20-deficient NK
cells and A20- and TNF compound–deficient NK cells in addition
to TNF levels in serum and in ex vivo–cultured splenocytes in
different A20 mutant mouse lines.
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